Table 7.
The risk factors of metastases of male lung cancer
| Author | Year | Histopathological type | Metastatic sites | Risk factor |
|---|---|---|---|---|
| Lina Wu et al 37 | 2017 | NSCLC | Lymph node | MicroRNA-422a |
| Chu Y et al 38 | 2017 | Adenocarcinoma | Lymph node | CLSTN1, CLU, NGAL |
| Brody R et al 39 | 2017 | NSCLC | NS | PD-L1 |
| Wu S et al 40 | 2016 | NSCLC | Lymph node | B7-H3 |
| Chen Y et al 41 | 2015 | NSCLC | Brain | NSE |
| Jain L et al 42 | 2009 | NS | NS | SNP |
| Oshiro Y et al43 | 2004 | Adenocarcinoma | Liver | AFP |
| Nikliński J et al 44 | 1992 | NSCLC | Lymph node | SCC |
| Hirashima T et al45 | 2000 | NSCLC | NS | telomere |
| Pollán M et al46 | 2003 | NSCLC | NS | CA-125 |
| Zhou Y et al47 | 2017 | NS | Bone | CA-125, ALP |
| Cedrés S et al 48 | 2011 | NSCLC | Brain | CEA, CYFRA21-1, |
| Dan Liu et al 49 | 2017 | Adenocarcinoma | Brain, lymph node | CA-125 |
| Chen F et al50 | 2015 | NS | Lymph node | CYFRA21-1, CEA |
| Lee DS et al51 | 2012 | NSCLC | Brain | CEA |
| Morita S et al52 | 2019 | NSCLC | Intertrabecular Vertebral | CEA |
| Shetty D et al53 | 2016 | NSCLC | Thyroid gland, lymph node | PSMA |
Abbreviations: NS, not specific; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma antigen; CLSTN1, calsyntenin-1; CLU, clusterin; NGAL, neutrophil gelatinase-associated lipocalin; SNP, single nucleotide polymorphisms; PD-L1, programmed cell death-1; B7-H3, B7 homolog 3; PSMA, prostate-specific membrane antigen.